TY  - JOUR
AV  - none
JF  - Cancer Letters
VL  - 411
A1  - Pistollato, Francesca
A1  - Calderón Iglesias, Rubén
A1  - Ruiz Salces, Roberto
A1  - Aparicio Obregón, Silvia
A1  - Crespo Alvare, Jorge
A1  - Dzul Lopez, Luis
A1  - Giampieri, Francesca
A1  - Battino, Maurizio
N2  - Among gynaecological cancers, ovarian cancer represents the leading cause of death in women. Current treatment for ovarian cancer entails surgery followed by combined chemotherapy with platinum and taxane, which are associated, particularly cisplatin, with severe side effects. While this treatment approach appears to be initially effective in a high number of patients, nearly 70% of them suffer a relapse within a few months after initial treatment. Therefore, more effective and better-tolerated treatment options are clearly needed. In recent years, several natural compounds (such as curcumin, epigallocatechin 3-gallate (EGCG), resveratrol, sulforaphane and Withaferin-A), characterized by long-term safety and negligible and/or inexistent side effects, have been proposed as possible adjuvants of traditional chemotherapy. Indeed, several in vitro and in vivo studies have shown that phytocompounds can effectively inhibit tumor cell proliferation, stimulate autophagy, induce apoptosis, and specifically target ovarian cancer stem cells (CSCs), which are generally considered to be responsible for tumor recurrence in several types of cancer. Here we review current literature on the role of natural products in ovarian cancer chemoprevention, highlighting their effects particularly on the regulation of inflammation, autophagy, proliferation and apoptosis, chemotherapy resistance, and ovarian CSC growth.
TI  - The use of natural compounds for the targeting and chemoprevention of ovarian cancer
ID  - uninimx145
UR  - http://doi.org/10.1016/j.canlet.2017.09.050
SN  - 0304-3835
SP  - 191
Y1  - 2017///
KW  - Ovarian cancer; Chemotherapy resistance; Natural compounds; Autophagy; Apoptosis; Ovarian cancer stem-like cells.
EP  - 200
ER  -